Innoviva Inc. (INVA)
NASDAQ: INVAHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
INVA stock chart
Technical analysisKey statistics
All statistics- Market cap
- $1.31B
- P/E (TTM)
- 7.83
- Forward P/E
- 8.33
- EPS (TTM)
- $2.35
- Dividend yield
- None
- Ex-dividend date
- Sep 8, 2015
- 52-week range
- 18.19 – 25.15
- Day range
- 18.33 – 18.79
- Volume / Avg
- 1.15M / 865.66K
- Beta
- —
- Shares outstanding
- 71.08M
52-week range
INVA stock today
Innoviva (INVA) closed at $18.41 on Nov 20, essentially unchanged from the prior close, versus the S&P 500's 3.70% decline. At this level, INVA sits near the bottom of its 52-week range of $18.19 to $25.15: 26.8% below the high, set on Feb 26, 2026 and 1.2% above the low. INVA is down 7.9% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 12.2%.
Innoviva trades at 7.8x its trailing twelve-month earnings per share of $2.35. Its forward P/E of 8.3x is higher than the trailing multiple, which means analysts expect earnings to decline over the next year.
Summary generated from market data by MetaCap's automated system. Methodology
About Innoviva
Company profileInnoviva, Inc. operates as a biopharmaceutical company in the United States and internationally. Its royalty portfolio includes RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol, and an inhaled corticosteroid, and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist, umeclidinium bromide, and ABA, VI.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Mr. Pavel Raifeld C.F.A.
- Headquarters
- Burlingame, CA
- Employees
- 159
- IPO year
- 2004
- Website
- inva.com
Financial highlights
Full financialsIn fiscal 2025, Innoviva generated $411.3 million in revenue, up 14.7% from fiscal 2024, its 2nd consecutive year of revenue growth. Net income was $271.2 million (+1059.2% year over year), for a net margin of 65.9% versus a median of 66.5% in the prior 5 years. Gross margin was 74.8% (down from 82.6%) and operating margin 39.8%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $411.33M | $358.71M | $310.46M | $331.34M | $391.87M |
| Growth | +14.67% | +15.54% | -6.30% | -15.45% | +16.35% |
| Net income | $271.17M | $23.39M | $179.72M | $220.26M | $368.84M |
| EPS (diluted) | $3.30 | $0.36 | $2.20 | $2.37 | $2.87 |
Analyst forecast
ForecastConsensus (5 analysts)
buy
Avg. price target
$34.80+89.03%
- Strong buy 0
- Buy 4
- Hold 0
- Sell 1
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 4, 2026
- EPS actual vs est.
- $-1.03 vs $0.49
- Surprise
- -310.20%
Dividends
Dividend history- Annual dividend
- $0.00
- Last payment
- $0.25
- Ex-dividend date
- Sep 8, 2015
INVA news
All INVA news- Innoviva gains new Overweight at Piper Sandler on diversified strategySeeking Alpha
- Replenish Your Portfolio With These 5 Low Price-to-Sales StocksNasdaqPBF, GPRE, INVA, PARR
- INVA or MRK: Which Is the Better Value Stock Right Now?NasdaqINVA, MRK
- Innoviva Reports Third Quarter 2026 Financial Results; Highlights Recent Company ProgressBusiness Wire
- Pfizer (PFE) Surpasses Q3 Earnings and Revenue EstimatesNasdaqPFE, INVA
- AbbVie (ABBV) Tops Q3 Earnings and Revenue EstimatesNasdaqABBV, INVA
- Eli Lilly (LLY) Surpasses Q3 Earnings and Revenue EstimatesNasdaqLLY, INVA
- INVA vs. MRK: Which Stock Is the Better Value Option?NasdaqINVA, MRK
Innoviva peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| NUVBNuvation Bio Inc. Class A | 3.80 | -0.26% | $1.34B | vs INVA |
| NBTXNanobiotix S.A. ADR | 26.50 | -2.98% | $1.35B | vs INVA |
| PAHCPhibro Animal Health Corporation Class A | 33.29 | -2.32% | $1.35B | vs INVA |
| AVLNAvalyn Pharma Inc. | 28.40 | -1.05% | $1.26B | vs INVA |
| URGNUroGen Pharma Ltd. | 27.65 | -12.86% | $1.36B | vs INVA |
| QUREuniQure N.V. | 19.35 | -4.35% | $1.36B | vs INVA |
| LBRXLB Pharmaceuticals Inc | 38.85 | -2.97% | $1.26B | vs INVA |
| RAPPRapport Therapeutics Inc. | 23.16 | -1.82% | $1.37B | vs INVA |
Indexes, lists and sector
Innoviva stock FAQ
What is Innoviva's stock price today?
INVA last traded at $18.41 as of Nov 20, 4:00 PM EST, up 0.00% on the day. Prices are delayed at least 15 minutes.
Does Innoviva pay a dividend?
Yes. Innoviva pays $0.00 per share annually. The most recent dividend of $0.25 had an ex-dividend date of Sep 8, 2015.
What is INVA's P/E ratio?
INVA trades at a trailing P/E ratio of 7.83 and a forward P/E of 8.33.
Who is Innoviva's CEO?
Mr. Pavel Raifeld C.F.A. is the chief executive officer of Innoviva Inc., which has about 159 employees.
Has INVA ever split its stock?
Yes. The most recent INVA stock split was a 1241-for-1000 split on Jun 3, 2014.
What is the INVA 52-week high?
The 52-week high for INVA is $25.15 and the 52-week low is $18.19. The stock is currently 26.8% below its high.